• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Risk of cardiovascular events similar between degludec and glargine in type 2 diabetics: The DEVOTE trial

byDayton McMillan
August 24, 2017
in Cardiology, Chronic Disease, Endocrinology, Nephrology, Ophthalmology, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Type 2 diabetic patients at high-risk for cardiovascular events treated with the ultra long-acting insulin degludec experienced cardiovascular events at an incidence noninferior to patients treated with glargine.

2. Patients treated with degludec experienced lower rates of severe hypoglycemic events compared to those treated with glargine.

Evidence Rating: 1 (Excellent)

Study Rundown: Patients with type 2 diabetes are at elevated risk for cardiovascular events. Prior studies have reported differing changes in risk of cardiovascular events for type 2 diabetics treated towards varied levels of glycemic control, with some suggesting intensive glycemic control raises risk for cardiovascular events. This study sought to determine if degludec, an ultra long-lasting basal insulin, was noninferior to the basal insulin glargine in terms of cardiovascular event risk. An international, randomized, double-blind trial recruited type 2 diabetics with a high risk for cardiovascular events. Patients were randomized to receive either degludec or glargine as their basal insulin and followed to assess for death due to cardiovascular events, hypoglycemic events, and adverse events. Patients treated with degludec experienced rates of death due to cardiovascular events noninferior to those treated with glargine. Additionally, degludec treated patients experienced a lower rate of severe hypoglycemic events. This study’s strengths include its enrollment of many patients with high cardiovascular risk, though the follow-up time of 2 years may limit its generalization to patients treated with degludec for longer periods of time.

Click to read the study, published today in NEJM

Relevant Reading: Ultra‐long‐acting insulin degludec has a flat and stable glucose‐lowering effect in type 2 diabetes

In-Depth [randomized controlled trial]: This randomized, double-blind study recruited 7637 patients from 2013-2014 at many international sites and followed them for 2 years. Eligible patients had type 2 diabetes at high risk for cardiovascular events and were being treated with at least one antihyperglycemic agent, though once in the trial they discontinued any basal insulin they were on prior to the study. Randomization in a 1:1 fashion placed patients in either degludec (n = 3818) or glargine (n = 3819) groups. Patients took their basal insulin in a manner and dose defined by the study. The primary outcome of this study was time-to-event analysis of death from cardiovascular causes, and secondary outcomes included events of severe hypoglycemia, and adverse events.

RELATED REPORTS

Sodium-glucose cotransporter 2 inhibitors reduce heart failure hospitalization in type 2 diabetes patients

The ACCORD trial: Intensive glucose control associated with increased mortality [Classics Series]

Aberrant levels of B12 and folate may be associated with increased risk of cardiovascular death in patients with diabetes

The primary outcome occurred in 8.5% (325/3818) of the degludec and 9.3% (356/3819) of the glargine groups (hazard ratio, 0.91; 95% confidence interval [CI], 0.78-1.06; p < 0.001 for noninferiority). No difference was detected in incidence of death between the degludec and glargine groups (5.3% vs 5.8%, respectively; hazard ratio, 0.91; 95% CI, 0.76-1.11; p = 0.35). Per 100 patient-years, 3.70 and 6.25 severe hypoglycemic events occurred in the degludec and glargine groups, respectively (rate ratio, 0.60; 95% CI, 0.48-0.76; p < 0.001 for superiority). There was no significant difference between groups regarding changes of glycated hemoglobin levels during the trial, and a mean glycated hemoglobin level level of 7.5% was found in both groups at the end of the trial. Adverse events occurred at a rate of 44.7 and 50.1 events per 100 patient-years in the degludec and glargine groups, respectively. The results of this study indicate treatment of type 2 diabetics at high risk for cardiovascular disease with degludec is noninferior to treatment with glargine in terms of incidence of cardiovascular events.

Image: PD

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: degludecglarginetype 2 diabetes
Previous Post

Continuous glucose monitoring associated with better glucose control for patients receiving insulin for type 2 diabetes

Next Post

2 Minute Medicine Rewind August 21, 2017

RelatedReports

Mediterranean diet linked to reduced diabetes risk in high risk cardiovascular patients
Cardiology

Sodium-glucose cotransporter 2 inhibitors reduce heart failure hospitalization in type 2 diabetes patients

June 18, 2022
Classics Series, Landmark Trials in Medicine
Emergency Classics

The ACCORD trial: Intensive glucose control associated with increased mortality [Classics Series]

May 4, 2022
Cardiology

Aberrant levels of B12 and folate may be associated with increased risk of cardiovascular death in patients with diabetes

April 4, 2022
Food environment associated with gestational diabetes
Chronic Disease

Prevalence of diabetes mellitus in China, 2013-2018

December 29, 2021
Next Post
Factors contributing to parents providing alcohol sips to adolescents

2 Minute Medicine Rewind August 21, 2017

Severity of emphysema on pulmonary CT may predict lung cancer location

Small-molecule inhibitor may reduce chemotherapy-associated metastases [PreClinical]

CRISPR-Cas9 corrects hypertrophic cardiomyopathy gene mutation in human preimplantation embryos [PreClinical]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Lisocabtagene maraleucel improves survival for relapsed or refractory large B-cell lymphoma
  • Fazirsiran reduces Z-AAT protein production in alpha1-antitrypsin deficiency
  • Arterial chemoembolization improves survival in non-resectable hepatocellular carcinoma [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.